logo
Share SHARE
FONT-SIZE Plus   Neg

ARRIS Group Q1 Profit Down - Quick Facts

ARRIS Group Inc. (ARRS) announced preliminary and unaudited financial results for the first quarter 2012. GAAP net income in the first quarter 2012 was $5.80 million or $0.05 per share, compared to $11.56 million or $0.09 per share in the year ago quarter.

Adjusted net income in the first quarter 2012 was $0.19 per share, compared to $0.16 per diluted share for the first quarter 2011.

Revenues in the first quarter 2012 were $302.9 million as compared to first quarter 2011 revenues of $267.4 million.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.15 per share on revenues of $296.35 million for the quarter. Analysts' estimates typically exclude special items.

For the second quarter 2012, the company now project that revenues will be in the range of $330 to $350 million, with adjusted net income per share in the range of $0.20 to $0.24 and GAAP net income per share in the range of $0.10 to $0.14.

Analysts expect the company to report earnings of $0.20 per share on revenues of $312.32 million for the second-quarter.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT